Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2

CP Wu, SH Hsiao, YS Wu - Drug Resistance Updates, 2023 - Elsevier
The overexpression of the human ATP-binding cassette (ABC) transporters in cancer cells is
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …

Recent advances in boosting EGFR tyrosine kinase inhibitors-based cancer therapy

Q Pan, Y Lu, L Xie, D Wu, R Liu, W Gao… - Molecular …, 2023 - ACS Publications
Epidermal growth factor receptor (EGFR) plays a key role in signal transduction pathways
associated with cell proliferation, growth, and survival. Its overexpression and aberrant …

The ABCG2/BCRP transporter and its variants–from structure to pathology

B Sarkadi, L Homolya, T Hegedűs - FEBS letters, 2020 - Wiley Online Library
The ABCG2 protein has a key role in the transport of a wide range of structurally dissimilar
endo‐and xenobiotics in the human body, especially in the tissue barriers and the …

Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance

N Anreddy, P Gupta, RJ Kathawala, A Patel… - Molecules, 2014 - mdpi.com
Tyrosine kinases (TKs) play an important role in pathways that regulate cancer cell
proliferation, apoptosis, angiogenesis and metastasis. Aberrant activity of TKs has been …

Reversing chemotherapy resistance by a synergy between lysosomal pH-activated mitochondrial drug delivery and erlotinib-mediated drug efflux inhibition

F Cheng, Q Pan, W Gao, Y Pu, K Luo… - ACS Applied Materials & …, 2021 - ACS Publications
Mitochondrial drug delivery has attracted increasing attention in various mitochondrial
dysfunction-associated disorders such as cancer owing to the important role of energy …

[HTML][HTML] Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells

J Kopecka, I Campia, A Jacobs, AP Frei, D Ghigo… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Multidrug resistance (MDR) in cancer cells is a challenging phenomenon often associated
with P-glycoprotein (Pgp) surface expression. Finding new ways to bypass Pgp-mediated …

Avapritinib: a selective inhibitor of KIT and PDGFRα that reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines

CP Wu, S Lusvarghi, JC Wang, SH Hsiao… - Molecular …, 2019 - ACS Publications
The frequent occurrence of multidrug resistance (MDR) conferred by the overexpression of
ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 in cancer cells remains a …

Advances in emerging drugs for osteosarcoma

CM Hattinger, M Fanelli, E Tavanti, S Vella… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: Osteosarcoma (OS), the most common primary malignant bone tumor, is
currently treated with pre-and postoperative chemotherapy in association with the surgical …

Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors

E Gazzano, B Rolando, K Chegaev… - Journal of controlled …, 2018 - Elsevier
Drug efflux transporters, in particular P-glycoprotein (Pgp), limit the success of
chemotherapy. We previously found that synthetic doxorubicin conjugated with nitric oxide …

Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase

FJ Giles, HM Kantarjian, PD Le Coutre, M Baccarani… - Leukemia, 2012 - nature.com
Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and
imatinib-resistant or-intolerant patients with chronic myeloid leukemia (CML) in chronic …